Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae

Chinese Journal of Infection and Chemotherapy

Volumn 10, Issue 1, 2010, Pages 13-16

  Guo, Bei Ning ^a   Yu, Ji Cheng ^a   Zhang, Jing ^a   Cao, Guo Ying ^a   Shi, Yao Guo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Fluoroquinolones; Mutant prevention concentration; Streptococcus pneumoniae

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN;

AGAR DILUTION; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG HALF LIFE; INOCULATION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

EID: 76149128025     PISSN: 10097708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolones studies [J]. Clin Infect Dis, 2001, 33 (Suppl 3) : S147-156.
2. Drlica K. The mutant selection window and antimicrobial resistance [J]. J Antimicrob Chemother, 2003, 52(1) : 11-17.
3. Chinese source
4. Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers [J]. Antimicrob Agents Chemother, 2000, 44(10) : 2600-2603.
5. Blondeau JM, Zhao X, Hansen G, et al. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae[J]. Antimicrob Agents Chemother, 2001, 45(2) : 433-438.
6. Chinese source